Global Knee Osteoarthritis Market, By Treatment Type (Medication, Surgery, Therapy), Route of Administration (Oral, Parenteral, Others), Dosage Form (Tablets, Injections, Others), Diagnosis (Imaging Tests, Joint Fluid Analysis, Blood Tests, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029
Market Analysis and Size
In recent years, the knee osteoarthritis market is anticipated to grow rapidly during the forecast period. According to the World Health Organization, around 10% to 15% of all persons over the age of 60 have osteoarthritis, with women having a higher prevalence than males. According to the United Nations, adults over the age of 60 will make up more than 20% of the global population by 2050. A conservative estimate of 15 percent of this 20 percent will have symptomatic osteoarthritis, with one-third of this cohort seriously afflicted. Knee osteoarthritis (OA), commonly known as the degenerative joint disease of the knee, is caused by wear and strain and gradual articular cartilage loss.
Data Bridge Market Research analyses that the knee osteoarthritis market was valued at USD 5.9 billion in 2021 and is expected to reach USD 12.02 billion by 2029, registering a CAGR of 9.30% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Knee osteoarthritis, often known as degenerative arthritis of the knee, is an inflammation of the knee joints. Degenerative arthritis is a type of wear-and-tear arthritis that typically affects adults over the age of 50, but it can also affect those younger than that. The cartilage in the knee joint eventually wears away as a result of knee osteoarthritis. The protective region between the bones shrinks as the cartilage wears away, causing the knee joint to become ragged and harsh. Bone spurs form as a result of friction between the bones. Some of the most common causes of this sickness include repetitive stress injuries, heavy and strenuous employment, ageing, weight increase, inherited anomalies, and other conditions such as metabolic issues and rheumatoid arthritis.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2019 - 2014)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Treatment Type (Medication, Surgery, Therapy), Route of Administration (Oral, Parenteral, Others), Dosage Form (Tablets, Injections, Others), Diagnosis (Imaging Tests, Joint Fluid Analysis, Blood Tests, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd.(Israel), Sanofi (France), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Novartis AG (Switzerland), Zydus Cadila (India), Boehringer Ingelheim International GmbH. (Germany), Apotex Inc. (Canada), AstraZeneca (UK), Horizon Therapeutics PLC (Ireland), Johnson & Johnson (US), Bayer AG (Germany), Perrigo Company plc (Ireland), Tolmar Pharmaceuticals, Inc. (US), Reckitt Benckiser Group PLC (UK), Sun Pharmaceutical Industries Ltd. (India), Assertio Therapeutics, Inc. (US), DAIICHI SANKYO COMPANY, LIMITED (Japan)
|
|
Market Opportunities
|
|
Knee Osteoarthritis Market Dynamics
Drivers
- Increasing prevalence of osteoarthritis
The rising prevalence of osteoarthritis is estimated to enhance the knee osteoarthritis market's growth. Injury, obesity, and a variety of other factors contribute to osteoarthritis. The damaged bodily part has severe joint pain and stiffness. Swelling of joints, tingling in the legs and limbs, and a reduction in range of motion are all indications of osteoarthritis.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of the knee osteoarthritis market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.
- Growing number of geriatric population
The surging geriatric population is estimated to enhance the market's expansion during the forecast period of 2022-2029. According to the World Health Organization (WHO), the worldwide geriatric population, which was estimated to be over 524 million in 2010, is expected to increase to nearly 2 billion by 2050. Due to their compromised immune systems, geriatrics are more susceptible to knee osteoarthritis, further estimated to enhance the market's growth rate.
Furthermore, rising initiatives by public and private organizations to spread awareness will expand the knee osteoarthritis market. Additionally, rise in the incidences of knee osteoarthritis among the general population and sedentary lifestyle of people will result in the expansion of knee osteoarthritis market.
Opportunities
- Increase in the number of research and development activities
Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the knee osteoarthritis market growth. Along with this, rising drug approvals and launches will further propel the market's growth rate.
Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the knee osteoarthritis market growth during the forecast period.
Restraints/Challenges
On the other hand, the high cost associated with the treatment will obstruct the market's growth rate. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the knee osteoarthritis market. Additionally, strict regulatory policies and lack of awareness among people will restrain and further impede the market's growth rate during the forecast period of 2022-2029.
This knee osteoarthritis market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the knee osteoarthritis market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
The most prevalent type of arthritis identified is knee osteoarthritis, and its prevalence will continue to climb as life expectancy and obesity increase. According to various sources, symptomatic knee osteoarthritis affects around 13% of women and 10% of men aged 60 and over. The frequency increases to as high as 40% among persons over 70. Males have a lower prevalence of knee osteoarthritis than females.
Knee osteoarthritis market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Knee Osteoarthritis Market
Over the projected period, the knee osteoarthritis market was expected to be constrained by the COVID-19 outbreak. Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. COVID-19, a new coronavirus, was identified as the causal agent in the pneumonia cases. This virus spread quickly over the world, killing a large number of people. COVID-19 was labelled a global pandemic by the World Health Organization (WHO) in March 2020, and rigorous measures to prevent the disease's spread were recommended. Since then, the pandemic has delayed the expansion of the healthcare sector and disrupted the supply chain. Furthermore, governments in many nations had imposed nationwide lockdowns to halt the spread of COVID-19. Similarly, healthcare organizations in numerous nations throughout the world were having difficulty continuing their supply chain activities. The supply chain slowness hampered the knee osteoarthritis market.
Global Knee Osteoarthritis Market Scope
The knee osteoarthritis market is segmented on the basis of treatment type, diagnosis, dosage form, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Treatment Type
- Medication
- Duloxetine
- Acetaminophen
- Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
- Surgery
- Joint Replacement
- Realigning Bones
- Lubrication Injections
- Cortisone Injections
- Therapy
- Transcutaneous Electrical Nerve Stimulation (TENS)
- Occupational Therapy
- Physical Therapy
Diagnosis
- Imaging Tests
- Magnetic resonance imaging (MRI)
- X-rays
- Joint Fluid Analysis
- Blood Tests
- Others
Dosage form
- Tablets
- Injections
- Others
Route of Administration
- Oral
- Parenteral
- Others
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Knee Osteoarthritis Market Regional Analysis/Insights
The knee osteoarthritis market is analysed and market size insights and trends are provided by country, treatment type, diagnosis, dosage form, route of administration, end-users and distribution channel as referenced above.
The countries covered in the knee osteoarthritis market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the knee osteoarthritis market because of the launch of new treatment options in this region. Additionally, rising healthcare expenditure along with the availability of treatment options will further propel the market's growth rate in this region.
Asia-Pacific are expected to grow during the forecast period due to the presence of generic manufacturers in this region. Also, the development of healthcare infrastructure and rising geriatric population will further propel the market's growth rate in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Knee Osteoarthritis Market Share Analysis
The Knee osteoarthritis market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to knee osteoarthritis market.
Some of the major players operating in the knee osteoarthritis market are:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (US)
- Teva Pharmaceutical Industries Ltd.(Israel)
- Sanofi (France), Pfizer Inc. (US)
- GlaxoSmithKline plc (UK)
- Novartis AG (Switzerland)
- Zydus Cadila (India)
- Boehringer Ingelheim International GmbH. (Germany)
- Apotex Inc. (Canada)
- AstraZeneca (UK)
- Horizon Therapeutics PLC (Ireland)
- Johnson & Johnson (US)
- Bayer AG (Germany)
- Perrigo Company plc (Ireland)
- Tolmar Pharmaceuticals, Inc. (US)
- Reckitt Benckiser Group PLC (UK)
- Sun Pharmaceutical Industries Ltd. (India)
- Assertio Therapeutics, Inc. (US)
- DAIICHI SANKYO COMPANY, LIMITED (Japan)
SKU-